The Q32 Bio Inc. (QTTB) SEC filings page on Stock Titan provides access to the company’s U.S. Securities and Exchange Commission disclosures, including current reports on Form 8-K that highlight material events. Q32 Bio’s filings reflect its status as a Nasdaq-listed clinical stage biotechnology company focused on alopecia areata and other autoimmune and inflammatory diseases.
Recent Form 8-K filings referenced by Q32 Bio include reports furnished under Item 2.02 for quarterly financial results and corporate updates, and under Item 8.01 for other events such as clinical trial milestones. For example, the company has filed 8-Ks in connection with press releases announcing financial results for specific quarters, as well as an 8-K describing the completion of enrollment in Part B of the SIGNAL-AA Phase 2a clinical trial of bempikibart for alopecia areata. Another 8-K details leadership changes under Item 5.02, including the resignation of a Chief Medical Officer and the appointment of an interim Chief Medical Officer.
Q32 Bio’s 8-K filings also confirm that its common stock, with a par value of $0.0001 per share, is registered pursuant to Section 12(b) of the Exchange Act and trades on Nasdaq under the symbol QTTB. The filings typically attach press releases as exhibits, which are incorporated by reference where specified, and clarify whether the information is being furnished rather than filed for purposes of Section 18 of the Exchange Act.
On Stock Titan, these SEC documents are updated as they become available from EDGAR and are paired with AI-powered summaries that explain the key points in accessible language. Users can quickly see which filings relate to financial results, clinical trial updates, leadership changes, or other corporate events, and can review the underlying forms and exhibits for more detail.
Q32 Bio Inc. director Mary Thistle received a corrected grant of 10,826 stock options on June 12, 2026. The options have an exercise price of $12.64 per share, expire on June 11, 2036, and vest in full on the earlier of June 12, 2027 or the next annual stockholders’ meeting, subject to continued service.
OrbiMed Advisors LLC and related investment entities report beneficial ownership of 4,127,987 shares of Q32 Bio Inc. common stock, representing 13.9% of the outstanding class. The amendment reflects that their percentage stake fell by more than 1% because shares outstanding increased to 29,708,814.
Within this total, OrbiMed Private Investments VII, LP holds 3,502,987 shares (about 11.8% of the company), and OrbiMed Genesis Master Fund, L.P. holds 625,000 shares (about 2.1%). OrbiMed Advisors, as managing member or general partner of affiliated entities, may be deemed to share voting and investment power over these positions through its investment committees.
The investors state they may buy more or sell shares over time depending on Q32 Bio’s business and market conditions but do not outline specific corporate-change plans. OrbiMed funds OPI VII and Genesis, and director Diyong Xu, are also subject to a 45‑trading‑day lock-up after the final prospectus, restricting sales, transfers, and hedging transactions, after which shares can be sold subject to Rule 144 and other securities laws.
Q32 Bio Inc. reported that Chief Scientific Officer Shelia M. Violette acquired 37,500 shares of common stock on July 16, 2026 from the vesting of performance-based restricted stock units tied to a financing of at least $100,000,000 in gross proceeds. These PSUs are also subject to a time-based condition and will vest in equal quarterly installments over three years from July 1, 2026, contingent on her continued service. Following this award, she holds 130,569 shares directly and 36,277 shares indirectly through Violette Holdings LLC, where she disclaims beneficial ownership beyond any pecuniary interest.
Q32 Bio Inc. CEO Jodie Pope Morrison reported an acquisition of 132,000 shares of common stock tied to performance-based restricted stock units granted on July 6, 2026. The PSUs met a financing performance condition and remain subject to quarterly vesting over three years, bringing her direct holdings to 353,104 shares.
Q32 Bio Inc. officer Lee Kalowski, its CFO and President, reported an acquisition of 53,250 shares of common stock on July 16, 2026, via a grant of performance-based restricted stock units (PSUs). Each PSU represents a contingent right to one share, and his direct holdings increased to 142,443 shares.
The PSUs were granted on July 6, 2026 and are tied to a performance-based condition linked to the closing of a financing of at least $100,000,000 in gross proceeds on or before December 31, 2026, and a time-based condition under which they vest in equal quarterly installments over three years from July 1, 2026, subject to continued service.
Q32 Bio Inc., a clinical-stage biotech focused on therapies for alopecia areata and other autoimmune diseases, has filed a resale registration covering up to 6,875,000 shares of common stock. This includes 6,725,000 outstanding shares and 150,000 shares issuable upon exercise of pre-funded warrants issued in a May 26, 2026 PIPE financing.
The shares may be sold from time to time by selling stockholders through various methods; Q32 Bio is not selling any shares and will receive no proceeds from these resales, other than nominal cash if pre-funded warrants are exercised. Common stock trades on Nasdaq as QTTB, which closed at $15.21 on July 16, 2026.
The company’s lead candidate, bempikibart (ADX-914), is in a Phase 2a trial (SIGNAL-AA Part B) for alopecia areata, with an open-label extension underway. Q32 Bio previously sold its ADX-097 complement asset to Akebia but retains other tissue-targeted complement programs and is a smaller reporting company under SEC rules.
Q32 Bio Inc. entered an underwriting agreement for a public offering of equity securities. The company is issuing 6,027,399 shares of common stock at $18.25 per share and pre-funded warrants to purchase up to 4,931,506 shares of common stock at $18.2499 per warrant, with a $0.0001 exercise price per share. Underwriters also have a 30-day option to buy up to 1,643,835 additional shares.
The company expects net proceeds of about $187.6 million, or $215.8 million if the underwriters fully exercise the option, and plans to use them for working capital, including research, clinical development, and commercialization efforts such as advancing bempikibart into future clinical trials. Pre-funded warrants are immediately exercisable, subject to an Ownership Limit of 4.99% or 9.99%, adjustable up to 19.99% with 61 days’ notice, and will not be listed on an exchange.
Q32 Bio Inc. is conducting a primary offering of 6,027,399 shares of common stock and pre-funded warrants to purchase up to 4,931,506 shares at $18.25 per share (or $18.2499 per warrant), for total public offering proceeds of $199,999,523.0994 and estimated net proceeds of about $187.59 million.
Shares outstanding will be 29,708,814 after the transaction, or 31,352,649 if the underwriters’ option for 1,643,835 additional shares is exercised in full, excluding any warrant exercises; this is a baseline figure, not the amount being offered. New investors incur immediate dilution of about $8.13 per share relative to the as adjusted net tangible book value of $10.12.
The company plans to use the cash, together with existing funds, for working capital, including research, clinical development and commercialization, particularly advancing its alopecia areata candidate bempikibart into future trials. Q32 Bio highlights favorable 36‑week safety and pharmacokinetic data from the SIGNAL‑AA Part B study and notes repayment of approximately $6.8 million to terminate its loan with Silicon Valley Bank, while emphasizing that its stock and the non‑listed pre‑funded warrants can be volatile and illiquid and that investing involves significant risks.
Q32 Bio Inc. is conducting a primary offering of up to $200,000,000 of common stock and pre-funded warrants under an effective shelf registration, with underwriters holding a 30-day option to buy up to an additional $30,000,000 of common stock. The transaction also covers shares issuable upon exercise of the pre-funded warrants, which are exercisable immediately at $0.0001 per share, subject to ownership caps, and are not expected to trade on an exchange.
The company is a clinical-stage biotechnology firm focused on bempikibart (ADX-914) for alopecia areata and other autoimmune diseases. Part B of the Phase 2a SIGNAL-AA trial in 33 severe patients used a 36-week subcutaneous dosing regimen and showed a generally well-tolerated safety profile without treatment-related serious adverse events, while an open-label extension from Part A indicated durable hair growth supporting maintenance dosing. Management plans to advance bempikibart into a registration-directed program in the first half of 2027.
Q32 Bio previously reoriented its strategy around bempikibart, including a 2025 asset sale of ADX-097 to Akebia Therapeutics while retaining earlier-stage complement assets. As of March 31, 2026, net tangible book value was $46.3 million, or $3.17 per share, with 14,629,463 shares outstanding before subsequent PIPE and at-the-market issuances. On June 24, 2026, the company repaid approximately $6.8 million, terminating its loan with Silicon Valley Bank.